Target Biotech ApS Financials, key figures and credit report
Gross profit -19.3 kDKK FY 2025 +23.9% vs 2024
EBIT -19.3 kDKK FY 2025 +35.8% vs 2024
Net debt 377.4 kDKK FY 2025 +343.3% vs 2024
Quick ratio 1.0 FY 2025 -11.7 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 487.08 | 402.82 | 63.83 | -25.41 | -19.34 |
| Employee benefit expenses | - 373.94 | - 330.00 | -57.77 | -4.74 | |
| EBIT | 113.14 | 72.83 | 6.06 | -30.15 | -19.34 |
| Other financial income | 10.37 | 13.76 | |||
| Other financial expenses | -0.72 | -1.03 | -0.41 | -1.61 | |
| Net income from associates (fin.) | 23 972.81 | -7 021.23 | |||
| Pre-tax profit | 112.42 | 72.83 | 5.03 | 23 952.62 | -7 028.42 |
| Income taxes | -24.70 | -16.10 | -1.11 | ||
| Net earnings | 87.72 | 56.72 | 3.93 | 23 952.62 | -7 028.42 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Holdings in group member companies | 20.00 | 20.00 | |||
| Participating interests | 18.00 | 23 990.81 | 10 750.67 | ||
| Investments total | 20.00 | 20.00 | 18.00 | 23 990.81 | 10 750.67 |
| Non-current loans receivable | 2.00 | ||||
| Long term receivables total | 2.00 | ||||
| Inventories total | |||||
| Current trade debtors | 199.56 | 61.25 | |||
| Current owed by particip. interest comp. | 134.98 | 371.32 | |||
| Current other receivables | 8.50 | ||||
| Current deferred tax assets | 22.00 | 16.09 | 12.00 | 6.00 | 6.00 |
| Short term receivables total | 221.56 | 77.34 | 12.00 | 149.48 | 377.32 |
| Cash and bank deposits | 223.98 | 257.47 | 454.95 | 170.32 | 162.78 |
| Cash and cash equivalents | 223.98 | 257.47 | 454.95 | 170.32 | 162.78 |
| Balance sheet total (assets) | 465.54 | 354.81 | 484.95 | 24 310.61 | 11 292.76 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Retained earnings | 134.42 | 222.14 | 278.87 | 282.79 | 17 714.33 |
| Profit of the financial year | 87.72 | 56.72 | 3.93 | 23 952.62 | -7 028.42 |
| Shareholders equity total | 272.14 | 328.87 | 332.79 | 24 285.42 | 10 735.91 |
| Provisions | -0.00 | ||||
| Non-current liabilities total | |||||
| Current trade creditors | 9.92 | 10.00 | 13.13 | ||
| Current owed to participating | 141.14 | 15.20 | 540.21 | ||
| Short-term deferred tax liabilities | 24.70 | 25.95 | 1.11 | ||
| Other non-interest bearing current liabilities | 168.70 | 3.52 | |||
| Current liabilities total | 193.40 | 25.95 | 152.16 | 25.20 | 556.85 |
| Balance sheet total (liabilities) | 465.54 | 354.81 | 484.95 | 24 310.61 | 11 292.76 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated